EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Oral smoothened inhibitors for Gorlin syndrome: A clinical review

Alexandra Baczynski, Brian Cahn, Brandon Worley, Roger Haber, Murad Alam

Journal of the American Academy of Dermatology · 2024

DOI: 10.1016/j.jaad.2024.06.047 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of the American Academy of Dermatology, 2024. Verfasst von Alexandra Baczynski und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Rush University Medical Center, Chicago, Illinois. Electronic address: baczyns2@uic.edu. Hauptthemen laut MEDLINE: Basal Cell Nevus Syndrome, Smoothened Receptor, Skin Neoplasms, Pyridines. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Although smoothened inhibitors (SMOi) have demonstrated efficacy in the management of basal cell carcinoma, no guidelines are available on how to utilize SMOi in the treatment of Gorlin syndrome (GS). This review's objective is to assess the clinical response to SMOi in GS, provide practical guidance for clinicians, and identify areas for future research. Through comprehensive searches of previous publications and expert opinion, this review demonstrates that intermittent dosing of SMOi and daily dosing have similar efficacy. While the adverse events of SMOi may result in their discontinuation during treatment of GS, intermittent dosing may improve compliance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Basal Cell Nevus SyndromeSmoothened ReceptorSkin NeoplasmsPyridinesHumansAdministration, OralAnilidesTreatment OutcomeMaleFemaleAntineoplastic AgentsQuinazolinesBiphenyl CompoundsDrug Administration ScheduleBenzimidazolesPhenylurea Compounds

Stichwörter der Autor:innen

Gorlin syndromeHedgehog inhibitorsNevoid basal cell carcinoma syndromeoral smoothened inhibitorssmoothened inhibitorssonidegibsystemic therapyvismodegib

Substanzen

Smoothened ReceptorHhAntag691PyridinessonidegibSMO protein, humanAnilidesglasdegibAntineoplastic AgentsQuinazolinesBiphenyl Compounds

Autor:innen und Institutionen

  • Department of Dermatology, Rush University Medical Center, Chicago, Illinois. Electronic address: baczyns2@uic.edu.
  • Department of Dermatology, College of Medicine, University of Illinois, Chicago, Illinois.
  • Florida Dermatology and Skin Cancer Centers, Winter Haven, Florida.
  • Feinberg School of Medicine's, Department of Dermatology, Northwestern University, Chicago, Illinois.

Zitieren

APA

Baczynski, A., Cahn, B., Worley, B., Haber, R., & Alam, M. (2024). Oral smoothened inhibitors for Gorlin syndrome: A clinical review. Journal of the American Academy of Dermatology. https://doi.org/10.1016/j.jaad.2024.06.047

Vancouver

Baczynski A, Cahn B, Worley B, Haber R, Alam M. Oral smoothened inhibitors for Gorlin syndrome: A clinical review. Journal of the American Academy of Dermatology. 2024. doi:10.1016/j.jaad.2024.06.047

BibTeX
@article{Baczynski2024,
  author = {Baczynski, Alexandra and Cahn, Brian and Worley, Brandon and Haber, Roger and Alam, Murad},
  title = {Oral smoothened inhibitors for Gorlin syndrome: A clinical review},
  journal = {Journal of the American Academy of Dermatology},
  year = {2024},
  doi = {10.1016/j.jaad.2024.06.047}
}
Kostenlos starten →